EyePoint Q2 revenue falls 44%, net loss widens

EyePoint

06/08/2025 12:33

Overview

EyePoint Q2 revenue falls to $5.3 mln from $9.5 mln year-over-year

Operating expenses rise to $67.6 mln due to DURAVYU trial costs

Net loss widens to $59.4 mln from $30.8 mln in prior year

Outlook

EyePoint expects cash reserves to fund operations into 2027

Company anticipates topline Phase 3 data for DURAVYU in 2026

EyePoint preparing for potential NDA filing with registration batches

Company sees DURAVYU first-to-market among sustained release treatments

Result Drivers

TRIAL COSTS - Increase in operating expenses attributed to DURAVYU Phase 3 trial costs for wet AMD

REVENUE DECLINE - Revenue decrease due to lower recognition of deferred revenue from YUTIQ product rights license

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$5.33 mln
Q2 Net Income
-$59.43 mln
Q2 Basic EPS
-$0.85
Q2 Operating Expenses
$67.56 mln
Q2 Operating Income
-$62.23 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for EyePoint Pharmaceuticals Inc is $27.50, about 60.4% above its August 5 closing price of $10.89

Press Release: ID:nGNX90vZR8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)